Drug Profile

AKB 9090

Alternative Names: AKB-9090

Latest Information Update: 02 Mar 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Akebia Therapeutics
Class Small molecules
Mechanism of Action Hypoxia-inducible factor-proline dioxygenase inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes
Available For Licensing Yes

Highest Development Phases

Preclinical Acute kidney injury
Research Adult respiratory distress syndrome

Most Recent Events

24 Feb 2026 Akebia Therapeutics plans a phase I trial (In volunteers) in March 2026 (IV) (NCT07429006)
12 Jan 2026 Akebia Therapeutics plans a phase I trial for Acute kidney injury in first half of 2026
14 Mar 2024 AKB 9090 is available for licensing as of 14 Mar 2024. https://akebia.com/partnering/ (Akebia Therapeutics website, March 2024)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com